STOCK TITAN
  1. Home
  2. News
  3. JAZZ

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

News
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Rhea-AI Summary
Jazz Pharmaceuticals plc appoints Patrick Kennedy, an experienced leader, to its Board of Directors, enhancing the company's focus on creating value for shareholders. Kennedy's financial and operating expertise aligns with Jazz's growth-oriented approach, aiming to transform patients' lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
-
News
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Rhea-AI Summary
Jazz Pharmaceuticals appoints Philip Johnson as Executive Vice President and CFO, bringing over 35 years of financial experience to the leadership team. Johnson will oversee various financial functions and drive growth and diversification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
management
-
News
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) announces participation in upcoming investor conferences, including TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences
News
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) will report its 2023 full year and fourth quarter financial results on February 28, 2024. A live audio webcast will be hosted to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences earnings
-
News
Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals
Rhea-AI Summary
Jazz Pharmaceuticals' Chief People Officer discusses the innovative work model 'Jazz Remix' on the Future of HR Podcast, emphasizing flexible work environments and positive employee experiences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
-
News
How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1
Rhea-AI Summary
Jazz Pharmaceuticals, founded in 2003, has evolved over the past 20 years to include treatment options for hematologic cancers and solid tumors, bringing over 11 therapeutics to market. Co-founder Bruce Cozadd prioritizes a people-first and mission-driven culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
News
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has signed a definitive agreement to acquire Redx Pharma plc's KRAS inhibitor program. The deal includes an upfront payment of $10 million to Redx, with the potential for up to $870 million in milestone payments. The collaboration aims to advance preclinical KRAS candidates through IND-enabling studies, with Jazz taking responsibility for clinical development, regulatory activities, manufacturing, and commercialization. Redx is also eligible for royalties on future net sales. The transaction expands Jazz's early-stage oncology pipeline and aims to address the high unmet need for innovative treatment options for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
acquisition
-
News
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announces Phase 2 trial results for investigational drug JZP150 in PTSD, with disappointing outcomes. The trial did not meet the primary or key secondary endpoints, leading the company to reconsider further development in PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
clinical trial
-
News
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) to webcast corporate presentation at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
News
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) presented updated data from the Phase 2a trial of zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib and fulvestrant for HER2+/HR+ metastatic breast cancer at the 2023 San Antonio Breast Cancer Symposium. The study demonstrated a progression-free survival at six months of 67% and a median progression-free survival of 12 months in heavily pretreated patients. The combination therapy showed a confirmed objective response rate of 35% and a median duration of response of 15 months, with a manageable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
clinical trial
Stock JAZZ logo
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

#1014 Ranked by Market Cap
#2855 Ranked by Stock Gains
N/A Ranked by Dividends

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni